Allergeenextract huisstofmijt Medicine 03 December 2024 Extended indication House Dust Mite Allergy Trial In Children aged between 5 and 11 years. Therapeutic value No estimate possible yet Total cost Registration phase Clinical trials Product Active substance Allergeenextract huisstofmijt Domain Chronic immune diseases Reason of inclusion Indication extension IND Main indication Other chronic immune diseases Extended indication House Dust Mite Allergy Trial In Children aged between 5 and 11 years. Current proprietary name Already available biosimilars / generics Proprietary name Acarizax Manufacturer Alk Abello Portfolio holder Mechanism of action Unknown Route of administration Sublingual Therapeutical formulation Tablet Budgetting framework Extramural (GVS) Centre of expertise Additional remarks Registration Registration route Centralised (EMA) Type of trajectory Unknown Particularity Unknown ATMP No Submission date 2025 Expected Registration 2026 Orphan drug Unknown Registration phase Clinical trials Reimbursement Medicine sluice Additional remarks Primary completion datum in april 2023. Therapeutic value Current treatment options Loratadine en cetirizine. Deze medicijnen kunnen zowel bij allergie voor huisdieren als bij allergie voor de huisstofmijt gebruikt worden. Therapeutic value No estimate possible yet This assessment does not indicate any potential inclusion in the package. Substantiation Duration of treatment Frequency of administration 1 times a day Dosage per administration 12 SQ-HDM References NCT04145219 (MATIC) Additional remarks SQ-HDM is de dosiseenheid voor Acarizax. Expected patient volume per year Patient volume Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References GIP databank (1). Additional remarks In 2023 waren er 6.627 gebruikers van Acarizax (1). Het is niet precies bekend hoeveel mensen met huisstofmijtallergie tussen de 5 en 11 jaar zijn. Expected cost per patient per year Cost € > 1,206.00 This amount gives an indication of the total cost. It is the result of the average expected patient volume times the average cost per patient. both per year. References Medicijnkosten.nl (1). Additional remarks Acarizax lyophilisaat voor sublinguaal gebruik 12 SQ-HDM: €3,60 (inclusief BTW) (1). Gebaseerd op dagelijks doorlopend gebruik kost een behandeling Acarizax €1.206,30 per patiënt per jaar (exclusief BTW). Potential total cost per year Total cost Total cost for sluice Additional remarks Off label use Off label use Unknown Indications off label use References Additional remarks Indication extension Indication extensions Unknown Indication extensions References Additional remarks Other information Additional remarks